Online inquiry

IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3252MR)

This product GTTS-WQ3252MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Lombar radicular pain research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3252MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1260MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ3464MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AZD8895
GTTS-WQ3357MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ9044MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ5892MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ1337MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ10273MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ12543MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NV-01
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW